{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:20:33Z","timestamp":1783383633965,"version":"3.54.6"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T00:00:00Z","timestamp":1281916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has been proposed that aspirin (ASA) and other non\u2010steroidal anti\u2010inflammatory drug (NSAID)\u2010induced urticaria (UR)\/angioedema (AE) are mediated through inhibition of cyclooxygenase\u20101 (COX\u20101) enzymes. Therefore, drugs with COX\u20102 selectivity may be well tolerated in such patients. We investigated the safety of preferential COX\u20102 inhibitor meloxicam in subjects with UR or AE type intolerance reaction to classical ASA\/NSAIDs. Subjects with reliable or documented history of UR\/AE due to classical ASA\/NSAIDs underwent a single\u2010blinded, placebo\u2010controlled oral challenge with a cumulative dose of 7.5\u2003mg meloxicam on 2 separate days. One\u2010quarter and three\u2010quarter divided doses of placebo and the active drug were given at 1\u2010h intervals. A total of 116 patients (86 women and 30 men, mean age 39.6\u2003\u00b1\u200312.7\u2003years) were enrolled to the study. The rate of atopy was 25.9%. Mean duration of drug reaction was 87.4\u2003\u00b1\u2003110.8 (1\u2013720) months. Almost half of the patients were multi\u2010reactors. The most comorbid disease was asthma and the two most frequent NSAIDs inducing UR\/AE were paracetamol (19. 6%) and ASA (19%). No reaction to placebo was observed. Ten out of 116 patients (8.6%) developed mild UR\/AE, or only erythema and pruritus at a one\u2010quarter or cumulative dose of 7.5\u2003mg of meloxicam. The remaining subjects (91.4%) tolerated perfectly meloxicam challenge. This study indicates that 7.5\u2003mg meloxicam is a safe alternative for ASA\/NSAID\u2010intolerant UR\/AE patients. Intolerance reactions to meloxicam are much milder forms of the patients\u2019 historical ASA\/NSAID\u2010induced cutaneous reactions.<\/jats:p>","DOI":"10.1111\/j.1346-8138.2010.00948.x","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T03:48:37Z","timestamp":1282016917000},"page":"973-979","source":"Crossref","is-referenced-by-count":17,"title":["Safety of meloxicam in patients with aspirin\/non\u2010steroidal anti\u2010inflammatory drug\u2010induced urticaria and angioedema"],"prefix":"10.1111","volume":"37","author":[{"given":"\u00d6zlem","family":"G\u00d6KSEL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr","family":"AYDIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"MISIRLIGIL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz S.","family":"DEMIREL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"BAVBEK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,16]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-05659-5.00069-3"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208786369740"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta12110"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1081\/JAS-120026063"},{"key":"e_1_2_5_6_2","first-page":"57","article-title":"Rofecoxib, as a safe alternative for acetyl salicylic acid\/nonsteroideal anti\u2010inflammatory drug\u2010intolerant patients","volume":"16","author":"Bavbek S","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/JAS-51326"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01075.x"},{"key":"e_1_2_5_9_2","first-page":"215","article-title":"Tolerability of three selective cyclo\u2010oxygenase\u20102 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID\u2010sensitive patients","volume":"36","author":"Senna G","year":"2004","journal-title":"Allerg Immunol (Paris)"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.616"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62412-X"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03854.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096000"},{"key":"e_1_2_5_14_2","first-page":"393","article-title":"Nimesulide and meloxicam are safe alternative drugs for patients intolerant to nonstreoidal anti\u2010inflammatory drugs","volume":"35","author":"Senna G","year":"2003","journal-title":"Allergol Immunol (Paris)"},{"key":"e_1_2_5_15_2","first-page":"319","article-title":"Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics","volume":"28","author":"Karakaya G","year":"2000","journal-title":"Allergol Immunopathol"},{"key":"e_1_2_5_16_2","first-page":"329","article-title":"The multipl faces of nonsteroidal anti\u2010inflammatory drug hypersensitivity","volume":"14","author":"S\u00e1nchez\u2010Borges M","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62221-1"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203090-00002"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.056008803.x"},{"key":"e_1_2_5_20_2","first-page":"364","article-title":"Meloxicam tolerance in hypersensitivity to nonsteroidal anti\u2010inflammatory drugs","volume":"16","author":"Domingo MV","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62226-0"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1027\/0838-1925.19.2.44"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00244.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/02770909909075412"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61912-6"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62099-6"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61277-X"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.323"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-005-0067-z"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199300461-00065"},{"key":"e_1_2_5_31_2","first-page":"317","article-title":"Meloxicam\u2010associated anaphylactic reaction","volume":"16","author":"Bavbek S","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_5_32_2","first-page":"213","volume-title":"New Research on Aspirin and Health","author":"Bavbek S","year":"2007"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2010.00948.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1346-8138.2010.00948.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T18:00:56Z","timestamp":1698948056000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2010.00948.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,16]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1346-8138.2010.00948.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2010.00948.x","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,16]]}}}